September 30, 2020
CADTH patient group input for new neuromyelitis optica spectrum disorder treatment
Have your say on this topic by completing the MS Society of Canada survey below.
The MS Society of Canada will provide input on behalf of people with Neuromyelitis Optica Spectrum Disorder (NMOSD) to the Canadian Agency for Drugs and Technologies in Health (CADTH) as part of a new drug submission for satralizumab (Enspryng).
You do not have to be taking or have taken satralizumab to participate. We need input from all Canadians affected by NMOSD. Please fill out this short survey.